Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shree Ganesh Biotech has submitted a routine compliance filing under SEBI's Regulation 32(1) to the BSE, Calcutta Stock Exchange, and Metropolitan Stock Exchange. The company states that as of 31 December 2025, it has no unutilised funds remaining from any past public issue, rights issue, preferential issue, or Qualified Institutional Placement (QIP). Because there are no unutilised proceeds, the company is not providing the standard Annexure-A deviation/variation statement. The letter is signed by Wholetime Director Aman Patel, dated 29 January 2026.
This is a routine nil disclosure with no material impact on shareholders or stock price. It simply confirms regulatory compliance and that there is no leftover fundraising money to account for.